Pharma Microbiology Testing Kits Global Market Report 2024

The pharma microbiology testing kits market size has grown strongly in recent years. It will grow from $6.25 billion in 2023 to $6.77 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth observed in the historical period can be attributed to several factors, including an increased demand for pharmaceuticals, a rising prevalence of infectious diseases, the effects of globalization, an enhanced awareness regarding the significance of pharma microbiology testing, and the globalization of pharmaceutical manufacturing processes.

The pharma microbiology testing kits market size is expected to see strongly grown in the next few years. It will grow to $9.72 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. Anticipated growth in the forecast period can be attributed to several key factors, including the expanding use of automation in pharma microbiology testing, increased investments in research and development within this field, the growing adoption of new technologies in pharma microbiology testing, particularly in biopharmaceutical manufacturing and personalized medicine. Major trends expected during this period encompass rapid microbial testing methodologies, the emergence of point-of-care testing solutions, the utilization of single-use systems, the integration of digital technologies, and a focus on biosafety and biosecurity measures within the industry.

The pharma microbiology testing kits market is being propelled by the surge in infectious diseases globally. Diseases like Hepatitis A, B, and C, STDs, and HIV are on the rise, as highlighted by the CDC. In 2021, the WHO report noted approximately 1.4 million annual cases of Hepatitis a worldwide. Factors such as infected needle injections, unprotected sex, homelessness, and limited medical access contribute to the escalating instances of infectious diseases, thereby driving the demand for pharma microbiology testing kits.

A significant uptick in healthcare expenditure is anticipated to fuel growth in the pharma microbiology testing kits market. Heightened healthcare spending prompts healthcare facilities to prioritize robust infection control measures. Consequently, there's an increased need for frequent microbial contaminant and pathogen testing to ensure patient safety and compliance with regulatory standards. For instance, in 2021, U.S. Health care spending soared to $4.3 trillion, marking a 2.7 percent growth per person, as reported by the Centers for Medicare & Medicaid Services (CMS), underscoring the potential boost to the pharma microbiology testing kits market. Contracting out routine microbiological testing to specialized laboratories is gaining traction within the pharma microbiology testing kits market. This outsourcing strategy ensures stringent quality and safety standards for raw materials, intermediates, and end products. Contract testing labs manage various testing domains like stability testing, method validation, microbial testing, and batch-release testing. Notably, the global healthcare analytical testing market is projected to reach $4.13 billion by 2021, growing at an 11.3% rate, signaling the expanding reliance on outsourcing for such services.

Key players in the pharma microbiology testing kits market are prioritizing innovative technologies, notably artificial intelligence (AI), to enhance operational efficiency. AI integration into these testing kits aims to significantly improve the speed, accuracy, and overall efficiency of microbial detection and identification processes. In a prime example, in May 2021, Becton, Dickinson, and Company unveiled the use of AI to revolutionize urine testing within microbiology. This strategic move is poised to elevate the precision and efficiency of microbiology testing procedures, marking a notable advancement in the field.

In November 2022, IDEXX, a healthcare innovation company based in the US, acquired Tecta-PDS for an undisclosed sum. This strategic acquisition aims to broaden IDEXX's presence in the field of water microbiology testing. Tecta-PDS, headquartered in Canada, specializes in water microbiology testing services.

Major companies operating in the pharma microbiology testing kits market include F. Hoffmann-La Roche AG, Becton Dickinson and Company, Abbott Laboratories, ThermoFisher Scientific, SGS SA, Toxikon Corp., Pace Analytical Services, Boston Analytics, Charles River Laboratories International, Nelson Laboratories, Siemens healthcare AG, Hologic Inc., Neogen Corporation, Shimadzu Corporation, Merck KGaA, Agilent TechnologiesInc., QIAGEN N.V., Bruker Corporation, bioMérieux SA, Lucideon, Lonza Group AG, MilliporeSigma, Hardy Diagnostics, Sartorius AG, 3M Company, Waters Corporation, PerkinElmer Inc., Luminex Corporation.

North America was the largest region in the pharma microbiology testing kits market in 2023. Western Europe was the second-largest region in the global pharma microbiology testing kits market report. The regions covered in the pharma microbiology testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharma microbiology testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary products within pharma microbiology testing kits include consumables and equipment. Consumables are used specifically for detecting microbial limits in pharmaceutical products. These kits facilitate various tests such as endotoxin testing, sterility testing, microbial examination, environmental monitoring, among others. These testing procedures cater to end-users such as hospitals, diagnostic centers, custom lab service providers, academic institutions, and research institutes.

The pharma microbiology testing kits market research report is one of a series of new reports provides pharma microbiology testing kits market statistics, including pharma microbiology testing kits industry global market size, regional shares, competitors with a pharma microbiology testing kits market share, detailed pharma microbiology testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the pharma microbiology testing kits industry. This pharma microbiology testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharma microbiology testing kits market consists of sales of rapid test systems, common rapid test kits, rapid tests for salmonella, PCR test, and lateral flow. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.